Details of the Drug

General Information of Drug (ID: DMLCCGO)

Drug Name

Recombinant human cartilage-derived retinoic acid-sensitive protein depot

Synonyms

ST-03; MIA protein (osteochrondral defects),Scil; Melanoma inhibitory activity (osteochrondral defects), Scil; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects); RhCD-RAP (osteochrondral defects), Pfizer; RhCD-RAP (osteochrondral defects), Scil; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects), Pfizer; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects), Scil

Indication

Disease Entry	ICD 11	Status	REF
Articular cartilage disorder	FA34.Y	Phase 2/3	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D05ZDD

References

1	ClinicalTrials.gov (NCT00450203) Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer. U.S. National Institutes of Health.